Author:Qingfeng Pharmaceutical Group
Posted Time:2020-08-11 00:00
The Class 4 chemical generic Sorafenib tosylate tablets (trade name: Ligesitai®) developed by Jiangxi Shanxiang Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, were approved by the National Medical Products Administration on August 5, 2020. NMPA). The launch of Ligesitai®, announcing that we have officially entered the field of liver cancer treatment.
┃ Ligesitai® Sorafenib Tosylate Tablets
You are about to leave the website www.qfyy.com.cn
Continuing to visit this link will redirect you to another unfamiliar domain. Our privacy policy and terms no longer apply. Please be aware of the risks and protect your personal information.
Well. We will not display the risk warning when you exit from www.qfyy.com.cn.
